AI Unlocks Prostate Cancer Treatment Benefits

Written By : Isra Zaman

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2023-07-03 03:45 GMT | Update On 2023-07-03 09:47 GMT

Data from a new study published in NEJM Evidence shows promise for personalized use of short-term ADT in men with predominantly intermediate-risk prostate cancer. The study involved ArteraAI, a developer of multimodal artificial intelligence-based predictive and prognostic cancer tests, and other researchers including those from University Hospitals (UH) Seidman Cancer Center. The information validates the first-ever predictive AI biomarker of androgen deprivation therapy (ADT) benefit in prostate cancer.

The study used novel deep learning methodology and histopathology image data from more than 5,000 patients across five Phase 3 randomized trials, with long-term follow-up. Patients in these trials were enrolled from over 100 centers across the US and Canada. The predictive AI biomarker was developed using datasets comprising about 20% African American patients. In past U.S.-based clinical trials, African American men have made up only 10.8% of prostate cancer trial participants.

In patients with localized prostate cancer, ADT can be added to radiotherapy if improved patient outcomes are anticipated. Some studies suggest many men do not need ADT as part of their treatment plan, and that radiotherapy alone is effective. If given the opportunity to leverage the biomarker, most intermediate-risk patients could potentially avoid the morbidity and financial burden associated with ADT.

Ref: Artificial Intelligence Predictive Model for Hormone Therapy Use in Prostate Cancer, NEJM Evidence, DOI 10.1056/EVIDoa2300023

Full View

Article Source : NEJM Evidence

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Isra Zaman

Isra Zaman is a Life Science graduate from Daulat Ram College, Delhi University, and a postgraduate in Biotechnology from Amity University. She has a flair for writing, and her roles at Medicaldialogues include that of a Sr. content writer and a medical correspondent. Her news pieces cover recent discoveries and updates from the health and medicine sector. She can be reached at editorial@medicaldialogues.in.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

AI Unlocks Prostate Cancer Treatment Benefits

Similar News

Are cancer surgeries unknowingly eliminating the body's natural defense against cancer? Study sheds light

Study Finds Fatty Acids as Key Driver of Triple-Negative Tumor Growth

Women with This Common Condition Face Higher Risk of Gynaecological Cancer: Systematic Review Finds

New Imaging Technique Detects Prostate Cancer Recurrence with 70 Percent Accuracy: Study Finds

Is Social Isolation an Overlooked Risk Factor in Cancer Mortality? A New Study Explores

Importance of Identifying High-Risk Node-Positive Patients in EBC

Metabolically Active Visceral Fat May be Tied to Advanced Endometrial Cancer: Study Suggests

HPV Vaccine Offers Strong Protection-Even for the Unvaccinated: JAMA Pediatrics Study